Carine Dias Ferreira de Jesus

Carine Dias Ferreira de Jesus

Auto-generated profile, based on publicly available information

Carine Dias Ferreira de Jesus

Department of Pediatrics Pediatric Gastroenterology and Hepatology Unit Botucatu Medical School-São Paulo State University Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
CJCarine Dias Ferreira de Jesus
Carine Dias Ferreira de Jesus
MCMary de Assis Carvalho
Mary de Assis Carvalho
NMNilton carlos Machado
Nilton carlos Machado
De Jesus CD, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Nov;25(6):500-509. https://doi.org/10.5223/pghn.2022.25.6.500

17 July 2024 in Journal of Pediatrics & Neonatal Care
Verified
Journal Article
Open access
PDF file
NMNilton carlos Machado
Nilton carlos Machado
TWThabata Koester Weber
Thabata Koester Weber
JDJuliana Tedesco Dias
Juliana Tedesco Dias
GHGabriela Nascimento Hercos
Gabriela Nascimento Hercos
CJCarine Dias Ferreira de Jesus
Carine Dias Ferreira de Jesus
MCMary de Assis Carvalho
Mary de Assis Carvalho
Background: Celiac disease (CD) is chronic small bowel inflammation with villous atrophy, consequently, an immune-mediated disorder triggered by ingesting Gluten in wheat, barley, and rye in genetically susceptible individuals. Aims: Summarize the fundamental principles for managing the diet of patients with CD. This Mini-Review using relevant articles in PubMed's online databases followed the medical keywords Celiac Disease, Gluten, gluten-free diet, nutritional approach, and diet adherence. The institution's Ethics Committee has waived the need to review the ethical aspects of this text. The cornerstone of the treatment is the lifelong adherence to a Gluten-Free Diet (GFD). This dietary regimen, which forms the basis of the patient's treatment, requires eliminating all food components containing Gluten and its derivatives from the diet. However, the treatment approach has changed from focusing on food avoidance to a wide-ranging evaluation of the various factors influencing the dietary choices in the patient's life. The Global Approach to the Follow-up of Celiac Disease is based on 1) control of symptomatology and dietary adherence; 2) improving emotional and social wellness in treating CD patients, with the active involvement of a psychologist; and 3) ensuring successful education of both the child and the family about its management. Indeed, the impact of CD extends beyond the patient and affects the well-being of caregivers and 4) evaluate socioeconomic burden, considering that Gluten-free food products remain significantly more expensive than gluten-containing equivalents with variable availability. So, the GFD is the primary treatment for CD, and difficulties in managing the Disease can lead to impaired Quality of Life. In conclusion, strict adherence to the GFD is imperative, requiring a multidisciplinary team involving physicians, dietitians, and psychologists on a regular visit schedule to assess dietary adherence and avoid long-term complications.

1 January 2022 in Journal of Pediatrics & Neonatal Care
Verified
Journal Article
Open access
PDF file
NMNilton carlos Machado
Nilton carlos Machado
MCMary de Assis Carvalho
Mary de Assis Carvalho
CJCarine Dias Ferreira de Jesus
Carine Dias Ferreira de Jesus
DPDebora Avellaneda Penatti
Debora Avellaneda Penatti
JDJuliana Tedesco Dias
Juliana Tedesco Dias
Purpose: To evaluate pain intensity and the agreement between the Visual Analogue Scale (VAS) and Faces Pain Scale (FAS) in children/adolescents with Chronic Abdominal Pain (CAP) both in Irritable Bowel Syndrome (IBS) and Helicobacter pylori dyspepsia (HpD). Methods: Single-centre, observational, cross-sectional study including 217 children/ adolescents. Inclusion criteria: age (4-15 years); HpD diagnosis established with endoscopy and histopathological biopsies. IBS diagnosis based on Rome IV criteria. Exclusion criteria: chronic disorders (genetic, metabolic, cardiac, hepatic, renal diseases). In a standardized form, data was achieved, and children marked the “pain over the past month”. Results: The age of first symptoms, first visits, pain (epigastric, retrosternal, nocturnal pain, burning), vomiting, and anorexia were higher in HpD than in IBS children. The pain intensity was categorized as severe (7-10) for the majority of children both in FAS and VAS scales (p>.0.05). Also, analysis between IBS and HpD concerning sex, first child, age at first visit (≤10 y or >10y), overweight/obese, average BMI child, and the number of episodes of pain during the week (p>0.05). There was a positive and statistically significant correlation between FAS and VAS pain intensity in IBS (All children, male and female) and HpD group (only for All children). On Bland-Altman plots of VAS vs FAS, the 2SD values of differences between scales were: IBS (3.8) and HpD (3.4) group. The calculated limits of agreement (95% CIs) exceeded the a priori limits of acceptability for all measured parameters, indicating that the scales are not interchangeable. Conclusions: Pain scales were, without difficulty performed, widely accepted and provided evidence that FAS and VAS are valid measures for assessing pain intensity in children with CAP. However, both VAS and FAS did not discriminate IBS from HpD, and the scales are not interchangeable.